Prognostic Values of MicroRNA-130 Family Expression in Patients with Cancer: a Meta-analysis and Database Test

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2019 Oct 24

PMID 31640738

Citations 9

Authors

Zhen Peng

Fujiao Duan

Jingjing Yin

Yajing Feng

Zhongyu Yang

Jia Shang

Affiliations

Soon will be listed here.

Abstract

Background: Emerging evidence shows that microRNA-130 (miRNA-130) family may be useful as prognostic biomarkers in cancer. However, there is no confirmation in an independent validation study. The aim of this study was to summarize the prognostic value of miRNA-130 family (miRNA-130a and miRNA-130b) for survival in patients with cancer.

Methods: The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to estimate the association strength between miRNA-130 family expression and prognosis. Kaplan-Meier plotters were used to verify the miRNA-130b expression and overall survival (OS).

Results: A total of 2141 patients with OS and 1159 patients with disease-free survival (DFS)/progression-free survival (PFS) were analyzed in evidence synthesis. For the miRNA-130a, the overall pooled effect size (HR) was HR 1.58 (95% CI: 1.21-2.06, P < 0.001). Tissue and serum expression of miRNA-130a was significantly associated with the OS (HR = 1.54, 95% CI: 1.11-2.14, P = 0.009; HR = 1.65, 95% CI: 1.14-2.38, P = 0.008), and in gastric cancer (HR = 1.81, 95% CI: 1.34-2.45, P < 0.001). For the miRNA-13b, a statistical correlation was observed between high miRNA-130b expression and poor OS in patients with cancer (HR = 1.95, 95% CI: 1.47-2.59, P < 0.001), especially in tissue sample (HR = 2.01, 95% CI: 1.39-2.91, P < 0.001), Asian (HR = 2.55, 95% Cl: 1.77-3.69, P < 0.001) and hepatocellular carcinoma (HR = 1.87, 95% CI: 1.23-2.85, P = 0.004). The expression of miRNA-130b was significantly correlated with DFS/PFS (HR = 1.53, 95% CI: 1.31-1.77, P < 0.001), in tissue (HR = 1.98, 95% CI: 1.50-2.62, P < 0.001) and serum (HR = 1.37, 95% CI: 1.15-1.64, P < 0.001), especially in HCC (HR = 1.98, 95% CI: 1.50, 2.62, P < 0.001). In database test, a significant correlation between high miRNA-130b expression and poor OS for HCC patients was observed (HR = 1.55, 95% CI: 1.01, 2.35, P = 0.0045).

Conclusion: The high expression of miRNA-130 family might predict poor prognosis in cancer patients. Prospectively, combining miRNA-130a and miRNA-130b may be considered as powerful prognostic predictor for clinical application.

Citing Articles

BCR-ABL1-driven exosome-miR130b-3p-mediated gap-junction Cx43 MSC intercellular communications imply therapies of leukemic subclonal evolution.

Chai C, Sui K, Tang J, Yu H, Yang C, Zhang H Theranostics. 2023; 13(12):3943-3963.

PMID: 37554265 PMC: 10405834. DOI: 10.7150/thno.83178.

Non-coding RNAs and gastrointestinal cancers prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.

Zha B, Luo Y, Kamili M, Zha X Front Oncol. 2023; 13:1193665.

PMID: 37546412 PMC: 10399243. DOI: 10.3389/fonc.2023.1193665.

Circulating MicroRNAs as Cancer Biomarkers in Liquid Biopsies.

Suarez B, Sole C, Marquez M, Nanetti F, Lawrie C Adv Exp Med Biol. 2022; 1385:23-73.

PMID: 36352210 DOI: 10.1007/978-3-031-08356-3_2.

A Novel miRNA-Based Model Can Predict the Prognosis of Clear Cell Renal Cell Carcinoma.

Wu J, Zhang F, Zhang J, Sun Z, Hao C, Cao H Technol Cancer Res Treat. 2021; 20:15330338211027923.

PMID: 34159861 PMC: 8237220. DOI: 10.1177/15330338211027923.

Plasma-Derived Exosomal microRNA-130a Serves as a Noninvasive Biomarker for Diagnosis and Prognosis of Oral Squamous Cell Carcinoma.

He T, Guo X, Li X, Liao C, Wang X, He K J Oncol. 2021; 2021:5547911.

PMID: 33953745 PMC: 8068531. DOI: 10.1155/2021/5547911.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G . MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. Int J Clin Exp Pathol. 2015; 8(1):384-93. PMC: 4348820. View

Aris M, Barrio M . Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol. 2015; 6:46. PMC: 4321613. DOI: 10.3389/fimmu.2015.00046. View

Peng W, Liu Y, Zhu S, Li W, Guo F . The correlation of circulating pro-angiogenic miRNAs' expressions with disease risk, clinicopathological features, and survival profiles in gastric cancer. Cancer Med. 2018; 7(8):3773-3791. PMC: 6089172. DOI: 10.1002/cam4.1618. View

Wang Y, Zhang X, Tang W, Lin Z, Xu L, Dong R . miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma. Cell Death Differ. 2017; 24(12):2089-2100. PMC: 5686346. DOI: 10.1038/cdd.2017.129. View

Kjersem J, Ikdahl T, Lingjaerde O, Guren T, Tveit K, Kure E . Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2013; 8(1):59-67. PMC: 5528512. DOI: 10.1016/j.molonc.2013.09.001. View

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

10.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

11.

He L, Wang H, Zhang L, Huang L, Li J, Xiong Y . Prognostic significance of low DICER expression regulated by miR-130a in cervical cancer. Cell Death Dis. 2014; 5:e1205. PMC: 4047899. DOI: 10.1038/cddis.2014.127. View

12.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

13.

Chang R, Xu J, Fang F, Yang H, Yang L . MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling. Tumour Biol. 2016; 37(8):10609-19. DOI: 10.1007/s13277-016-4919-z. View

14.

Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M, Laudanna C . MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia. 2013; 15(9):1086-99. PMC: 3769887. DOI: 10.1593/neo.13998. View

15.

Liu X, Pan B, Sun L, Chen X, Zeng K, Hu X . Circulating Exosomal miR-27a and miR-130a Act as Novel Diagnostic and Prognostic Biomarkers of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2018; 27(7):746-754. DOI: 10.1158/1055-9965.EPI-18-0067. View

16.

Gong X, Zhang K, Wang Y, Wang J, Cui Y, Li S . MicroRNA-130b targets Fmr1 and regulates embryonic neural progenitor cell proliferation and differentiation. Biochem Biophys Res Commun. 2013; 439(4):493-500. DOI: 10.1016/j.bbrc.2013.08.096. View

17.

Hu X, Li L, Wu H, Liu Y, Wang B, Tang Y . Serum miR-130b level, an ideal marker for monitoring the recurrence and prognosis of primary hepatocellular carcinoma after radiofrequency ablation treatment. Pathol Res Pract. 2018; 214(10):1655-1660. DOI: 10.1016/j.prp.2018.08.007. View

18.

Zhou Y, Li R, Yu H, Wang R, Shen Z . microRNA-130a is an oncomir suppressing the expression of in gastric cancer. Onco Targets Ther. 2017; 10:3893-3905. PMC: 5548272. DOI: 10.2147/OTT.S139443. View

19.

Wang M, Ji S, Shao G, Zhang J, Zhao K, Wang Z . Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients. Clin Transl Oncol. 2017; 20(7):906-911. DOI: 10.1007/s12094-017-1805-0. View

20.

Duan F, Wang K, Dai L, Zhao X, Feng Y, Song C . Prognostic significance of low microRNA-218 expression in patients with different types of cancer: Evidence from published studies. Medicine (Baltimore). 2016; 95(37):e4773. PMC: 5402571. DOI: 10.1097/MD.0000000000004773. View